Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 4th Quarter Results for Financial Year 2022-23.

The company recorded a Revenue of Rs.710 crore in Q4FY23 compared to Rs.666 crore in Q4FY22 registering a growth of 7%. EBITDA for the quarter is Rs.47 crore as compared to Rs.(22) crore in Q4FY22 registering a substantial growth of 314%.

The corresponding quarter of previous year includes revenue and profitability from UK Vaccines business.

Business Review:

Quarter ended 31st March, 2023:

* UK Business stood at Rs.242 crore in Q4FY23 compared to Rs.223 crore in Q3FY23 registering a growth of 8%. UK Business contributed about 36% of Global Revenue.

* India Business stood at Rs.125 crore in Q4FY23. India Business contributed 19% of the Global Revenue.

* Emerging Markets Business of the Company stood at Rs.173 crore in Q4FY23 compared to Rs.148 crore in Q3FY23 registering a growth of 16%. Emerging Markets Business contributed about 25% of the Global Revenue.

* Irish Business stood at Rs.44 crore in Q4FY23 compared to Rs.40 crore in Q3FY23 showing a growth of 10%.

*  US Business stood at Rs.50 crore in Q4FY23. US Business contributed 7% of the Global Revenue.

Research and Development expenditure during the quarter was at Rs.25 crore (3.5% to sales) and including capital expenditure was at 7.1% to sales.

Year ended 31st March, 2023:

*  UK Business stood at Rs.887 crore in FY23. UK Business contributed about 33% of Global Revenue.

* India Business stood at Rs.609 crore in FY23. India Business contributed 23% of the Global Revenue.

* Emerging Markets Business of the Company stood at Rs.555 crore in FY23. Emerging Markets Business contributed about 21% of the Global Revenue.

* Irish Business stood at Rs.158 crore in FY23 compared to Rs.153 crore in the previous year registering a growth of 4%.

* US Business stood at Rs.303 crore in FY23. US Business contributed 11% of the Global Revenue.

Research and Development expenditure during the period was at Rs.139 crore (5% to sales) and including capital expenditure was at 10% to sales.

Intellectual Property (IP):

2 patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239. The company was granted 3 patents during the quarter and now holds 810 patents.